Chimeric Antigenic Receptor (CAR) T Cells: A New Immunotherapeutic Strategy
Autor(a) principal: | |
---|---|
Data de Publicação: | 2019 |
Outros Autores: | , |
Tipo de documento: | Artigo |
Idioma: | por |
Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
Texto Completo: | https://doi.org/10.25756/rpf.v11i2-3.219 |
Resumo: | The development of T cells genetically modified to express a quimeric antigen receptor (CAR) at the surface, has been growing up in last few decades, envolving until now more than three hundred clinical trials in oncology. Expression of CAR allows to direct endogenous T cell anti-tumor activity to a given antigen, resulting in the destruction of a specific target. After promising results in several clinical trials, the Food and Drug Administration approved, in 2017, the first two medicines including CAR T cells – the Kymriah® (tisagenlecleucel), to treat relapsed/refractory B-cell acute lymphoblastic leukemia, from Novartis and the Yescarta® (axicabtagene ciloleucel), to treat B-cell lymphoma non-Hodgkin from Kite Pharma. Although this technology has already four generations, in clinical practice only the second generation is used. This article is focused on the cellular and molecular mechanisms behind the development of CAR T cells, their mechanism of action, potential adverse effects, as well as the clinical application of CAR T cells in oncology and future perspectives of this new cellular therapy. |
id |
RCAP_338afa26ab66f9945acbcc1d20570243 |
---|---|
oai_identifier_str |
oai:ojs.farmacoterapia.pt:article/222 |
network_acronym_str |
RCAP |
network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository_id_str |
7160 |
spelling |
Chimeric Antigenic Receptor (CAR) T Cells: A New Immunotherapeutic StrategyCélulas T com Recetor de Antigénio Quimérico (CAR): Uma Nova Estratégia ImunoterapêuticaThe development of T cells genetically modified to express a quimeric antigen receptor (CAR) at the surface, has been growing up in last few decades, envolving until now more than three hundred clinical trials in oncology. Expression of CAR allows to direct endogenous T cell anti-tumor activity to a given antigen, resulting in the destruction of a specific target. After promising results in several clinical trials, the Food and Drug Administration approved, in 2017, the first two medicines including CAR T cells – the Kymriah® (tisagenlecleucel), to treat relapsed/refractory B-cell acute lymphoblastic leukemia, from Novartis and the Yescarta® (axicabtagene ciloleucel), to treat B-cell lymphoma non-Hodgkin from Kite Pharma. Although this technology has already four generations, in clinical practice only the second generation is used. This article is focused on the cellular and molecular mechanisms behind the development of CAR T cells, their mechanism of action, potential adverse effects, as well as the clinical application of CAR T cells in oncology and future perspectives of this new cellular therapy.O desenvolvimento de células T geneticamente modificadas para expressarem à sua superfície um recetor de antigénio quimérico (CAR), tem sofrido uma grande evolução nas últimas décadas, envolvendo, até ao momento, mais de três centenas de ensaios clínicos em oncologia. A expressão do CAR permite direcionar a atividade anti-tumoral endógena das células T para um determinado antigénio, resultando na destruição de um alvo específico.Após a obtenção de resultados promissores em vários ensaios clínicos, a agência regulamentar Norte Americana aprovou, em 2017, os primeiros dois fármacos contendo células T CAR – o Kymirah®(tisagenlecleucel), para o tratamento da leucemia linfoblástica aguda das células B recidivante e/ou refratária, pertencente à Novartis e o Yescarta®(axicabtagene ciloleucel), para o tratamento de linfomas não Hodgkin das células B, pertencente à Kite Pharma. Apesar de esta tecnologia contar já com quatro gerações, na prática clínica o seu uso é limitado à segunda geração.Este artigo foca-se nos fundamentos celulares e moleculares subjacentes ao desenvolvimento das células T CAR, no seu mecanismos de ação, potenciais efeitos adversos, bem como na aplicação clínica das células T CAR em oncologia e perspetivas futuras desta nova terapia celular.Formifarma2019-10-14info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttps://doi.org/10.25756/rpf.v11i2-3.219https://doi.org/10.25756/rpf.v11i2-3.219Revista Portuguesa de Farmacoterapia / Portuguese Journal of Pharmacotherapy; Vol 11 No 2-3 (2019): Abril / Julho; 39-48Revista Portuguesa de Farmacoterapia; v. 11 n. 2-3 (2019): Abril / Julho; 39-482183-73411647-354Xreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAPporhttp://revista.farmacoterapia.pt/index.php/rpf/article/view/222http://revista.farmacoterapia.pt/index.php/rpf/article/view/222/195Direitos de Autor (c) 2019 Revista Portuguesa de Farmacoterapiahttp://creativecommons.org/licenses/by-nc-nd/4.0info:eu-repo/semantics/openAccessCruz, Maria TeresaMateus, Daniela MarquesBorges, Olga2023-09-01T04:34:14Zoai:ojs.farmacoterapia.pt:article/222Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T15:11:38.636287Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse |
dc.title.none.fl_str_mv |
Chimeric Antigenic Receptor (CAR) T Cells: A New Immunotherapeutic Strategy Células T com Recetor de Antigénio Quimérico (CAR): Uma Nova Estratégia Imunoterapêutica |
title |
Chimeric Antigenic Receptor (CAR) T Cells: A New Immunotherapeutic Strategy |
spellingShingle |
Chimeric Antigenic Receptor (CAR) T Cells: A New Immunotherapeutic Strategy Cruz, Maria Teresa |
title_short |
Chimeric Antigenic Receptor (CAR) T Cells: A New Immunotherapeutic Strategy |
title_full |
Chimeric Antigenic Receptor (CAR) T Cells: A New Immunotherapeutic Strategy |
title_fullStr |
Chimeric Antigenic Receptor (CAR) T Cells: A New Immunotherapeutic Strategy |
title_full_unstemmed |
Chimeric Antigenic Receptor (CAR) T Cells: A New Immunotherapeutic Strategy |
title_sort |
Chimeric Antigenic Receptor (CAR) T Cells: A New Immunotherapeutic Strategy |
author |
Cruz, Maria Teresa |
author_facet |
Cruz, Maria Teresa Mateus, Daniela Marques Borges, Olga |
author_role |
author |
author2 |
Mateus, Daniela Marques Borges, Olga |
author2_role |
author author |
dc.contributor.author.fl_str_mv |
Cruz, Maria Teresa Mateus, Daniela Marques Borges, Olga |
description |
The development of T cells genetically modified to express a quimeric antigen receptor (CAR) at the surface, has been growing up in last few decades, envolving until now more than three hundred clinical trials in oncology. Expression of CAR allows to direct endogenous T cell anti-tumor activity to a given antigen, resulting in the destruction of a specific target. After promising results in several clinical trials, the Food and Drug Administration approved, in 2017, the first two medicines including CAR T cells – the Kymriah® (tisagenlecleucel), to treat relapsed/refractory B-cell acute lymphoblastic leukemia, from Novartis and the Yescarta® (axicabtagene ciloleucel), to treat B-cell lymphoma non-Hodgkin from Kite Pharma. Although this technology has already four generations, in clinical practice only the second generation is used. This article is focused on the cellular and molecular mechanisms behind the development of CAR T cells, their mechanism of action, potential adverse effects, as well as the clinical application of CAR T cells in oncology and future perspectives of this new cellular therapy. |
publishDate |
2019 |
dc.date.none.fl_str_mv |
2019-10-14 |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://doi.org/10.25756/rpf.v11i2-3.219 https://doi.org/10.25756/rpf.v11i2-3.219 |
url |
https://doi.org/10.25756/rpf.v11i2-3.219 |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.relation.none.fl_str_mv |
http://revista.farmacoterapia.pt/index.php/rpf/article/view/222 http://revista.farmacoterapia.pt/index.php/rpf/article/view/222/195 |
dc.rights.driver.fl_str_mv |
Direitos de Autor (c) 2019 Revista Portuguesa de Farmacoterapia http://creativecommons.org/licenses/by-nc-nd/4.0 info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
Direitos de Autor (c) 2019 Revista Portuguesa de Farmacoterapia http://creativecommons.org/licenses/by-nc-nd/4.0 |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Formifarma |
publisher.none.fl_str_mv |
Formifarma |
dc.source.none.fl_str_mv |
Revista Portuguesa de Farmacoterapia / Portuguese Journal of Pharmacotherapy; Vol 11 No 2-3 (2019): Abril / Julho; 39-48 Revista Portuguesa de Farmacoterapia; v. 11 n. 2-3 (2019): Abril / Julho; 39-48 2183-7341 1647-354X reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository.name.fl_str_mv |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
repository.mail.fl_str_mv |
|
_version_ |
1799129986910650368 |